Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Valneva (VALN)
NASDAQ:VALN
Valneva (VALN) Stock Price & Analysis
166 Followers
VALN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.58 - $16.49
Previous Close$7.59
Volume1.77K
Average Volume (3M)11.88K
Market Cap
$520.68M
Enterprise Value$610.78M
Total Cash (Recent Filing)€126.08M
Total Debt (Recent Filing)€208.82M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 13, 2024EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding69,456,071
10 Day Avg. Volume9,682
30 Day Avg. Volume11,880
Standard Deviation0.25
R-Squared0.22
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)4.86
Price to Sales (P/S)3.24
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$26.00Price Target Upside251.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Valneva News
PremiumCompany Announcements
Valneava and Pfizer Nearing Lyme Vaccine Milestone
PremiumCompany Announcements
Valneva’s Chikungunya Vaccine Wins European Approval
PremiumCompany Announcements
Valneva Strengthens Board, Shareholders Back PlansPremiumCompany Announcements
Valneva’s Chikungunya Vaccine Approved in Canada
PremiumCompany Announcements
Valneva Announces General Meeting and Leadership Change
PremiumCompany Announcements
Valneva Engages Investors with Vaccine Pipeline Updates
PremiumCompany Announcements
Valneva Advances Lyme Disease Vaccine Candidate
PremiumCompany Announcements
Valneva’s Chikungunya Vaccine Nears EU ApprovalBulls Say, Bears Say
Bulls Say
Financial OutlookValneva expects Ixchiq sales to exceed €100M in year 3 of the commercial launch and anticipates the global market for chikungunya vaccines will exceed $500M per year.
Product LaunchThe EU’s Committee for Medicinal Products for Human Use adopted a positive opinion to recommend the granting of a marketing authorization for Valneva’s live attenuated single-shot chikungunya vaccine Ixchiq.
Regulatory ApprovalThe FDA granted Ixchiq accelerated approval for the prevention of disease caused by chikungunya virus in individuals 18 years of age and older who are at increased risk of exposure to CHIKV.
Bears Say
Financial PerformanceFY23 revenue of €153.7M, compared to €361.3M in 2022, indicating a significant decrease in revenue.
RevenueFY23 revenue dropped significantly compared to the previous year, suggesting potential financial instability.
RisksRisks include commercial, regulatory, development, manufacturing, financial/dilution, and liability challenges.
---
Ownership Overview
0.00%
Insiders
0.09% Mutual Funds
0.63% Other Institutional Investors
99.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
VALN FAQ
What was Valneva’s price range in the past 12 months?
Valneva lowest stock price was $6.58 and its highest was $16.49 in the past 12 months.
What is Valneva’s market cap?
Currently, no data Available
When is Valneva’s upcoming earnings report date?
Valneva’s upcoming earnings report date is Aug 13, 2024 which is in 23 days.
How were Valneva’s earnings last quarter?
Valneva released its earnings results on May 07, 2024. The company reported $0.884 earnings per share for the quarter, missing the consensus estimate of $1.12 by -$0.236.
Is Valneva overvalued?
According to Wall Street analysts Valneva’s price is currently Undervalued.
Does Valneva pay dividends?
Valneva does not currently pay dividends.
What is Valneva’s EPS estimate?
Valneva’s EPS estimate is -$0.34.
How many shares outstanding does Valneva have?
Valneva has 69,638,450 shares outstanding.
What happened to Valneva’s price movement after its last earnings report?
Valneva reported an EPS of $0.884 in its last earnings report, missing expectations of $1.12. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Valneva?
Currently, no hedge funds are holding shares in VALN
---
Valneva Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.00 (251.35% Upside)
$26.00 (251.35% Upside)
Blogger Sentiment
Bullish
VALN Sentiment 100%
Sector Average 71%
Sector Average 71%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.26%
12-Months-Change
Fundamentals
Return on Equity
-12.32%
Trailing 12-Months
Asset Growth
-15.28%
Trailing 12-Months
Company Description
Valneva
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travellers; one for the prevention of Japanese encephalitis (IXIARO) and the second (DUKORAL) for the prevention of cholera and diarrhoea. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, and third-party products; Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; and Technologies and services which relates to services and inventions at a commercialization stage. The group is based in France and operates internationally.
---
VALN Company Deck
---
VALN Earnings Call
Q1 2024
0:00 / 0:00
---
VALN Stock 12 Month Forecast
Average Price Target
$26.00
▲(251.35% Upside)
Technical Analysis
Best Analysts Covering VALN
1 Year
1 Year Success Rate
2/17 ratings generated profit
1 Year Average Return
-23.61%
reiterated a buy rating 24 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 11.76% of your transactions generating a profit, with an average return of -23.61% per trade.
---